SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+7.62%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$993M
AUM Growth
+$993M
(+10%)
Cap. Flow
+$136M
Cap. Flow
% of AUM
13.75%
Top 10 Holdings %
Top 10 Hldgs %
39.81%
Holding
126
New
24
Increased
29
Reduced
26
Closed
35
Top Buys
| 1 |
GSK
GSK
|
$34.2M |
| 2 |
Treace Medical Concepts
TMCI
|
$25M |
| 3 |
TG Therapeutics
TGTX
|
$20.5M |
| 4 |
Insulet
PODD
|
$20.4M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$18.4M |
Top Sells
| 1 |
Charles River Laboratories
CRL
|
$22.2M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$13.7M |
| 3 |
Arcellx
ACLX
|
$12.9M |
| 4 |
CVS Health
CVS
|
$11.3M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$9.95M |
Sector Composition
| 1 | Healthcare | 98.3% |
| 2 | Consumer Staples | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$13.8B
| $64.9M | 5.98% | 287,165 +44,430 | +18% | +$10M |
|
|
2
Teva Pharmaceuticals
TEVA
$21.1B
| $61.7M | 5.7% | 6,052,164 +1,802,164 | +42% | +$18.4M |
|
|
EDAP
3
EDAP TMS
EDAP
$84.5M
| $43.9M | 4.05% | 6,256,784 +782,562 | +14% | +$5.49M |
|
4
Surmodics
SRDX
$487M
| $39.5M | 3.64% | 1,230,862 -105,976 | -8% | -$3.4M |
|
5
Organogenesis Holdings
ORGO
$653M
| $39.1M | 3.61% | 12,296,163 +568,100 | +5% | +$1.81M |
|
|
6
GSK
GSK
$79.9B
| $34.2M | 3.15% | +943,000 | New | +$34.2M |
|
7
Humana
HUM
$36.5B
| $33.5M | 3.09% | 68,802 +6,052 | +10% | +$2.94M |
|
8
iRadimed
IRMD
$921M
| $27.9M | 2.57% | 628,206 -145,488 | -19% | -$6.46M |
|
9
Vaxcyte
PCVX
$4B
| $25.5M | 2.35% | 499,650 -71,600 | -13% | -$3.65M |
|
|
10
Treace Medical Concepts
TMCI
$464M
| $25M | 2.31% | +1,907,823 | New | +$25M |
|
|
11
TG Therapeutics
TGTX
$4.65B
| $24.1M | 2.22% | 2,884,382 +2,448,882 | +562% | +$20.5M |
|
12
Neuropace
NPCE
$303M
| $24M | 2.21% | 2,466,205 -9 | -0% | -$88 |
|
|
13
Arcellx
ACLX
$3.85B
| $23.1M | 2.13% | 643,777 -358,222 | -36% | -$12.9M |
|
14
Tango Therapeutics
TNGX
$747M
| $21.7M | 2% | 1,929,019 +152,122 | +9% | +$1.71M |
|
|
15
Insulet
PODD
$23.9B
| $20.4M | 1.88% | +127,680 | New | +$20.4M |
|
16
Evolus
EOLS
$494M
| $19M | 1.75% | 2,078,000 +1,061,000 | +104% | +$9.7M |
|
17
Axogen
AXGN
$743M
| $18.9M | 1.75% | 3,785,829 +1,995,831 | +111% | +$9.98M |
|
|
18
Charles River Laboratories
CRL
$8.04B
| $18.8M | 1.74% | 96,064 -113,432 | -54% | -$22.2M |
|
19
Celcuity
CELC
$2.17B
| $18.8M | 1.73% | 2,056,484 +133,201 | +7% | +$1.22M |
|
20
The Beauty Health Co
SKIN
$264M
| $16.9M | 1.56% | 2,806,720 +324,931 | +13% | +$1.96M |
|
21
Axsome Therapeutics
AXSM
$6.05B
| $16.6M | 1.53% | 237,500 +212,600 | +854% | +$14.9M |
|
22
Smith & Nephew
SNN
$16.3B
| $16.2M | 1.49% | 653,900 +164,632 | +34% | +$4.08M |
|
23
Rigel Pharmaceuticals
RIGL
$697M
| $16M | 1.48% | 14,803,015 +625,000 | +4% | +$675K |
|
24
Immunovant
IMVT
$2.56B
| $15.3M | 1.42% | 399,599 +226,000 | +130% | +$8.68M |
|
25
Krystal Biotech
KRYS
$4.27B
| $13.7M | 1.26% | 117,892 +7,700 | +7% | +$893K |
|